medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2020, Number 1

<< Back Next >>

Rev Mex Patol Clin Med Lab 2020; 67 (1)

Interpretation of biomarker of acute cardiac pathology vs chronic with the use of high sensitivity troponin I (HsCTnI) in population of the Third Level Hospital

Hernández-Ramírez J, Núñez-Martínez M, Domínguez-Silva J

Language: Spanish
References: 12
Page: 9-16
PDF size: 257.27 Kb.


ABSTRACT

Introduction: Patients who present in the emergency room with high suspicion of acute coronary syndrome (ACS) constitute a population at high risk of death. Clinical symptomatology and electrocardiographic findings are important for diagnosis, but the diagnosis of certainty is based on biomarker results. Ultrasensitive Troponin I cause uncertainty in its elevation in clinical situations other than acute myocardial infarction. Objective: Identification of diseases of intra and extra cardiac origin with a significant elevation of the biomarker. Material and methods: Observational and analytical retrospective study. We included 500 patients, minimum age 21 and maximum 93 years. Simple random selection, with clinical history, physical examination, electrocardiogram and troponin I determination. Results: 389 were men and 111 women with a 3.5: 1 ratio. 7.7% of cases were diagnosed with acute myocardial infarction with or without ST segment elevation. 35.7% correspond to exclusive cardiac pathology and 56.1% of extra cardiac origin. Conclusion: The biomarker must be part of the initial assessment, its serial determination identifies changes in concentration in hours, opens a wide picture of other pathologies and the physician is obliged not to consider it as an exclusive cardiac alarm.


REFERENCES

  1. Escobedo-De la Peña J. Prevalencia de dislipidemias en la ciudad de México y su asociación con otros factores de riesgo cardiovascular. Gaceta Medica de México. 2014; 150: 128-136.

  2. Santoló M, Guindo J. Marcadores biológicos de necrosis miocárdica. Revista Española de Cardiología. 2003; 56 (7): 703-720.

  3. Stat high sensitive troponin-I by Architecct system 2012.

  4. Pérez-Cervantes JP. La unidad de dolor torácico en el servicio de urgencias y el uso de escala PRETEST y troponina I ultrasensible. Nuevo abordaje con una vieja herramienta. An Med (Méx). 2018; 63 (1): 14-19.

  5. Barrett EK. Ganong. Fisiología médica. Fisiología cardiovascular. 25ª ed. Sección V 31:32. McGraw-Hill, Interamericana. 2016.

  6. Barba JR. Síndrome coronario agudo: marcadores de lesión miocárdica. Rev Mex Patol Clin. 2009; 54: 116-135.

  7. Keller T, Zeller T. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med. 2009; 361:868-877.

  8. Carlton E, Greenslade J. Evaluation of high-sensitivity cardiac troponin I levels in patients with suspected acute coronary syndrome. JAMA Cardiol. 2016; 1 (4): 405-412.

  9. Allan S, Ordoñez-Llanos J, Troponina cardiaca ultrasensible: de la teoría a la práctica clínica. Revista Española de Cardiología. 2013; 66 (9): 687-691.

  10. World Health Organization. Hypertension and coronary heart disease: classification and criteria for epidemiological studies. Technical report series number 168. Geneva: World Health Organization; 1959, p. 28.

  11. Tang WH, Francis GS, Morrow DA, Newby LK, Cannon CP, Jesse RL et al. National Academy of Clinical Biochemistry Laboratory medicine practice guidelines: clinical utilization of cardiac biomarker testing in heart failure. Circulation. 2007; 116: e99-e109.

  12. García A, Jerjes C, Martínez P, Azpiri JR, Autrey A, Martínez C. RENASICA II Registro Mexicano de Síndromes Coronarios Agudos. Arch Cardiol Mex. 2005; 75 (Supl. 1): S6-S19.




2020     |     www.medigraphic.com